TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines

A 2-year prospective study

Éric Toussirot, Laurent Mourot, Barbara Dehecq, Daniel Wendling, Émilie Grandclément, Gilles Dumoulin

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: To evaluate the long-term consequences of TNFα inhibitors on body composition and fat distribution, as well as changes in serum adipokines in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Methods: Eight patients with RA and twelve with AS requiring a TNFα inhibitor were prospectively followed for 2 years. Body composition was evaluated by dual X-ray absorptiometry and included measurements of total fat mass, lean mass, fat in the gynoid and android regions, and visceral fat. Serum leptin, total and high molecular weight (HMW) adiponectin, resistin, and ghrelin were also assessed. Results: There was a significant gain in body mass index (p = 0.05) and a tendency for weight (p = 0.07), android fat (p = 0.07), and visceral fat (p = 0.059) increase in patients with RA, while in AS, total fat mass significantly increased (p = 0.02) with a parallel weight gain (p = 0.07). When examining the whole population of patients, we observed after 2 years a significant increase in body weight (+1.9 %; p = 0.003), body mass index (+2.5 %; p = 0.004), total fat mass (+11.1 %; p = 0.007), and fat in the android region (+18.3 %; p = 0.02). There was a substantial, albeit nonsignificant gain in visceral fat (+24.3 %; p = 0.088). Lean mass and gynoid fat were not modified. No major changes were observed for serum leptin, total adiponectin, and ghrelin, while HMW adiponectin and the HMW/total adiponectin ratio tended to decrease (-15.2 %, p = 0.057 and -9.3 %, p = 0.067, respectively). Resistin decreased significantly (-22.4 %, p = 0.01). Conclusions: Long-term TNFα inhibition in RA and AS is associated with a significant gain in fat mass, with a shift to the android (visceral) region. This fat redistribution raises questions about its influence on the cardiovascular profile of patients receiving these treatments.

Original languageEnglish
Pages (from-to)951-961
Number of pages11
JournalEuropean Journal of Nutrition
Volume53
Issue number3
DOIs
Publication statusPublished - 1 Jan 2014
Externally publishedYes

Fingerprint

Adipokines
Rheumatic Diseases
varespladib methyl
Fats
Ankylosing Spondylitis
Prospective Studies
Adiponectin
Intra-Abdominal Fat
Rheumatoid Arthritis
Resistin
Ghrelin
Molecular Weight
Leptin
Body Composition
Body Mass Index
Serum
Body Fat Distribution
Photon Absorptiometry
Weight Gain
Body Weight

Keywords

  • Adipokines
  • Body composition
  • Cardiovascular risk
  • Fat mass
  • Resistin
  • TNFα inhibitors

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines : A 2-year prospective study. / Toussirot, Éric; Mourot, Laurent; Dehecq, Barbara; Wendling, Daniel; Grandclément, Émilie; Dumoulin, Gilles.

In: European Journal of Nutrition, Vol. 53, No. 3, 01.01.2014, p. 951-961.

Research output: Contribution to journalArticle

@article{67006ce2addc4ca7a66333fc30b12bfa,
title = "TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: A 2-year prospective study",
abstract = "Purpose: To evaluate the long-term consequences of TNFα inhibitors on body composition and fat distribution, as well as changes in serum adipokines in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Methods: Eight patients with RA and twelve with AS requiring a TNFα inhibitor were prospectively followed for 2 years. Body composition was evaluated by dual X-ray absorptiometry and included measurements of total fat mass, lean mass, fat in the gynoid and android regions, and visceral fat. Serum leptin, total and high molecular weight (HMW) adiponectin, resistin, and ghrelin were also assessed. Results: There was a significant gain in body mass index (p = 0.05) and a tendency for weight (p = 0.07), android fat (p = 0.07), and visceral fat (p = 0.059) increase in patients with RA, while in AS, total fat mass significantly increased (p = 0.02) with a parallel weight gain (p = 0.07). When examining the whole population of patients, we observed after 2 years a significant increase in body weight (+1.9 {\%}; p = 0.003), body mass index (+2.5 {\%}; p = 0.004), total fat mass (+11.1 {\%}; p = 0.007), and fat in the android region (+18.3 {\%}; p = 0.02). There was a substantial, albeit nonsignificant gain in visceral fat (+24.3 {\%}; p = 0.088). Lean mass and gynoid fat were not modified. No major changes were observed for serum leptin, total adiponectin, and ghrelin, while HMW adiponectin and the HMW/total adiponectin ratio tended to decrease (-15.2 {\%}, p = 0.057 and -9.3 {\%}, p = 0.067, respectively). Resistin decreased significantly (-22.4 {\%}, p = 0.01). Conclusions: Long-term TNFα inhibition in RA and AS is associated with a significant gain in fat mass, with a shift to the android (visceral) region. This fat redistribution raises questions about its influence on the cardiovascular profile of patients receiving these treatments.",
keywords = "Adipokines, Body composition, Cardiovascular risk, Fat mass, Resistin, TNFα inhibitors",
author = "{\'E}ric Toussirot and Laurent Mourot and Barbara Dehecq and Daniel Wendling and {\'E}milie Grandcl{\'e}ment and Gilles Dumoulin",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00394-013-0599-2",
language = "English",
volume = "53",
pages = "951--961",
journal = "European Journal of Nutrition",
issn = "1436-6207",
publisher = "D. Steinkopff-Verlag",
number = "3",

}

TY - JOUR

T1 - TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines

T2 - A 2-year prospective study

AU - Toussirot, Éric

AU - Mourot, Laurent

AU - Dehecq, Barbara

AU - Wendling, Daniel

AU - Grandclément, Émilie

AU - Dumoulin, Gilles

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To evaluate the long-term consequences of TNFα inhibitors on body composition and fat distribution, as well as changes in serum adipokines in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Methods: Eight patients with RA and twelve with AS requiring a TNFα inhibitor were prospectively followed for 2 years. Body composition was evaluated by dual X-ray absorptiometry and included measurements of total fat mass, lean mass, fat in the gynoid and android regions, and visceral fat. Serum leptin, total and high molecular weight (HMW) adiponectin, resistin, and ghrelin were also assessed. Results: There was a significant gain in body mass index (p = 0.05) and a tendency for weight (p = 0.07), android fat (p = 0.07), and visceral fat (p = 0.059) increase in patients with RA, while in AS, total fat mass significantly increased (p = 0.02) with a parallel weight gain (p = 0.07). When examining the whole population of patients, we observed after 2 years a significant increase in body weight (+1.9 %; p = 0.003), body mass index (+2.5 %; p = 0.004), total fat mass (+11.1 %; p = 0.007), and fat in the android region (+18.3 %; p = 0.02). There was a substantial, albeit nonsignificant gain in visceral fat (+24.3 %; p = 0.088). Lean mass and gynoid fat were not modified. No major changes were observed for serum leptin, total adiponectin, and ghrelin, while HMW adiponectin and the HMW/total adiponectin ratio tended to decrease (-15.2 %, p = 0.057 and -9.3 %, p = 0.067, respectively). Resistin decreased significantly (-22.4 %, p = 0.01). Conclusions: Long-term TNFα inhibition in RA and AS is associated with a significant gain in fat mass, with a shift to the android (visceral) region. This fat redistribution raises questions about its influence on the cardiovascular profile of patients receiving these treatments.

AB - Purpose: To evaluate the long-term consequences of TNFα inhibitors on body composition and fat distribution, as well as changes in serum adipokines in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Methods: Eight patients with RA and twelve with AS requiring a TNFα inhibitor were prospectively followed for 2 years. Body composition was evaluated by dual X-ray absorptiometry and included measurements of total fat mass, lean mass, fat in the gynoid and android regions, and visceral fat. Serum leptin, total and high molecular weight (HMW) adiponectin, resistin, and ghrelin were also assessed. Results: There was a significant gain in body mass index (p = 0.05) and a tendency for weight (p = 0.07), android fat (p = 0.07), and visceral fat (p = 0.059) increase in patients with RA, while in AS, total fat mass significantly increased (p = 0.02) with a parallel weight gain (p = 0.07). When examining the whole population of patients, we observed after 2 years a significant increase in body weight (+1.9 %; p = 0.003), body mass index (+2.5 %; p = 0.004), total fat mass (+11.1 %; p = 0.007), and fat in the android region (+18.3 %; p = 0.02). There was a substantial, albeit nonsignificant gain in visceral fat (+24.3 %; p = 0.088). Lean mass and gynoid fat were not modified. No major changes were observed for serum leptin, total adiponectin, and ghrelin, while HMW adiponectin and the HMW/total adiponectin ratio tended to decrease (-15.2 %, p = 0.057 and -9.3 %, p = 0.067, respectively). Resistin decreased significantly (-22.4 %, p = 0.01). Conclusions: Long-term TNFα inhibition in RA and AS is associated with a significant gain in fat mass, with a shift to the android (visceral) region. This fat redistribution raises questions about its influence on the cardiovascular profile of patients receiving these treatments.

KW - Adipokines

KW - Body composition

KW - Cardiovascular risk

KW - Fat mass

KW - Resistin

KW - TNFα inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84898778051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898778051&partnerID=8YFLogxK

U2 - 10.1007/s00394-013-0599-2

DO - 10.1007/s00394-013-0599-2

M3 - Article

VL - 53

SP - 951

EP - 961

JO - European Journal of Nutrition

JF - European Journal of Nutrition

SN - 1436-6207

IS - 3

ER -